📰 Priority Review News
Page 101 - Priority Review News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Priority Review. Real-time updates on events, politics, business and more.
July 7, 2022
FDA has accepted for Priority Review the BLA for mosunetuzumab for adults with R/R follicular lymphoma after >2 prior systemic therapies.
July 6, 2022
(RTTNews) - BioArctic ABs partner Eisai said that the U.S. Food and Drug Administration has accepted the Biologics License Application or BLA und...
July 6, 2022
SOUTH SAN FRANCISCO (dpa-AFX) - Genentech, a member of the Roche Group (RHHBY), said Wednesday that the U.S. Food and Drug Administration has accepted the company's Biologics License Application
July 6, 2022
Lunsumio (mosunetuzumab) could be the first CD20xCD3 T-cell engaging bispecific antibody approved by the FDA for the treatment of any type of non-Hodgkin lymphoma Application is based on results from the
July 6, 2022
The FDA has issued a Complete Response Letter regarding the New Drug Application for tebipenem HBr for complicated urinary tract infections.
July 6, 2022
STOCKHOLM, July 6, 2022 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai...
July 6, 2022
The FDA has accepted for Priority Review the BLA for lecanemab for the treatment of early Alzheimer disease.
July 6, 2022
/PRNewswire/ -- BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the U.S. Food and Drug Administration (FDA) has accepted...
July 6, 2022
STOCKHOLM, July 6, 2022 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the U.S. Food and Drug Administration (FDA) has accepted the Biologics
July 6, 2022
/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...